Ignacio
Bernabeu Morón
Hospital Universitario La Paz
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario La Paz (24)
2024
-
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-related cancer
-
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466
-
Glucose metabolism outcomes after pituitary surgery in patients with acromegaly
Pituitary
-
Integrative clinical, hormonal, and molecular data associate with invasiveness in acromegaly: REMAH study
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 421-433
-
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related Cancer, Vol. 31, Núm. 7
2023
-
Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population
The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202
-
Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Frontiers in Endocrinology, Vol. 14
2022
-
Data mining analyses for precision medicine in acromegaly: a proof of concept
Scientific Reports, Vol. 12, Núm. 1
-
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
Frontiers in Endocrinology, Vol. 13
2021
-
Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain
Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936
-
Pasireotide in the Personalized Treatment of Acromegaly
Frontiers in Endocrinology, Vol. 12
2020
-
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
Pituitary, Vol. 23, Núm. 2, pp. 129-139
-
Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly
Endocrine, Vol. 70, Núm. 3, pp. 575-583
2019
-
Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly
EBioMedicine, Vol. 43, pp. 537-552
2018
-
Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305
2016
-
Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY
Pituitary, Vol. 19, Núm. 2, pp. 127-137
2013
-
Changes in acromegaly treatment over four decades in Spain: Analysis of the Spanish Acromegaly Registry (REA)
Pituitary, Vol. 16, Núm. 1, pp. 115-121
-
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues
European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13
-
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, Vol. 16, Núm. 1, pp. 101-108